PE20221509A1 - Celula cho que expresa heterodimeros il-15 - Google Patents

Celula cho que expresa heterodimeros il-15

Info

Publication number
PE20221509A1
PE20221509A1 PE2022001548A PE2022001548A PE20221509A1 PE 20221509 A1 PE20221509 A1 PE 20221509A1 PE 2022001548 A PE2022001548 A PE 2022001548A PE 2022001548 A PE2022001548 A PE 2022001548A PE 20221509 A1 PE20221509 A1 PE 20221509A1
Authority
PE
Peru
Prior art keywords
cho cell
heterodimers
expresses
heterodimer
15ralpha
Prior art date
Application number
PE2022001548A
Other languages
English (en)
Inventor
Richard Gabriel
Thomas Jostock
Justyna Jozefczuk
Urs Ulrich Lohrig
Alexandre Aurelien Pons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20221509A1 publication Critical patent/PE20221509A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere al heterodimero de IL-15/IL-15Ralfa producido en una linea celular CHO, y metodo de produccion del heterodimero y metodo de tratamiento utilizando el heterodimero.
PE2022001548A 2020-02-05 2021-01-29 Celula cho que expresa heterodimeros il-15 PE20221509A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
PE20221509A1 true PE20221509A1 (es) 2022-10-04

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001548A PE20221509A1 (es) 2020-02-05 2021-01-29 Celula cho que expresa heterodimeros il-15

Country Status (21)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
TW (1) TW202142558A (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230398185A1 (en) 2020-10-26 2023-12-14 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
MX2023004879A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DEL CARCINOMA DE CÉLULAS ESCAMOSAS.
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
NZ596494A (en) * 2006-01-13 2013-07-26 Us Gov Nat Inst Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
PT2160401E (pt) * 2007-05-11 2014-10-30 Altor Bioscience Corp Moléculas de fusão e variantes de il-15
CA2727953C (en) 2008-08-22 2017-05-16 Magna Seating Inc. Disc recliner with reduced backlash
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EP2911684B1 (en) * 2012-10-24 2019-06-19 Novartis Ag Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
MX368664B (es) 2014-04-29 2019-10-10 Novartis Ag Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.
SI3235830T1 (sl) * 2014-12-19 2020-12-31 Jiangsu Hengrui Medicine Co., Ltd. Proteinski kompleks interlevkina 15 in njegove uporabe
JP7200104B2 (ja) * 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
CA3200275A1 (en) * 2016-10-21 2018-04-26 Nantcell, Inc. Multimeric il-15-based molecules
CN110177568A (zh) * 2017-01-20 2019-08-27 诺华股份有限公司 用于治疗癌症的组合疗法
US20220211815A1 (en) * 2018-02-02 2022-07-07 Novartis Ag Combination therapy for the treatment of cancer
US20210107961A1 (en) * 2018-03-01 2021-04-15 Glycotope Gmbh Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15

Also Published As

Publication number Publication date
BR112022014493A2 (pt) 2022-09-20
CL2023002447A1 (es) 2024-03-15
UY39062A (es) 2021-09-30
AU2021215893A1 (en) 2022-08-25
TW202142558A (zh) 2021-11-16
CL2022002094A1 (es) 2023-03-10
KR20220137651A (ko) 2022-10-12
CN115023436A (zh) 2022-09-06
AR121261A1 (es) 2022-05-04
JP2023145622A (ja) 2023-10-11
DOP2022000156A (es) 2022-10-16
MX2022009611A (es) 2022-11-07
ECSP22060286A (es) 2022-09-30
JP2022522566A (ja) 2022-04-20
EP4100425A1 (en) 2022-12-14
CO2022010860A2 (es) 2022-08-19
CA3168469A1 (en) 2021-08-12
JOP20220174A1 (ar) 2023-01-30
WO2021156720A1 (en) 2021-08-12
IL295278A (en) 2022-10-01
CR20220367A (es) 2022-08-30
US20210244821A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
PE20221509A1 (es) Celula cho que expresa heterodimeros il-15
TWD191091S (zh) 鞋面
TWD188400S (zh) 鞋面
TWD197377S (zh) 鞋面
PE20181147A1 (es) Emisor por goteo
TWD190032S (zh) 鞋面
PE20181271A1 (es) Composiciones que comprenden cepas bacterianas
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
CR20170390A (es) Heterociclos biciclicos como inhibidores de fgfr
CL2016001787A1 (es) Sumario post-manejo con tutorial
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
AR117416A1 (es) Derivados de oxadiazolina
CL2020000966A1 (es) Tratamiento de enfermedad mediada por smc
CL2022002540A1 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina
AR112587A1 (es) Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima
CL2015000882A1 (es) Optimización de cosecha para plantas susceptibles de estrés.
CR20150473S (es) Un sujetador de pelo y brazalete convertibles
BR112015018230A2 (pt) método para fabricação de um material conformado, e, material conformado
CO2024002924A2 (es) Nanopartícula para el desarrollo temprano de la resistencia del concreto, composición para formar el concreto, que incluye la misma, y método para producir la misma
RO133069A3 (ro) Sistem şi dispozitiv de iluminat cu diode electroluminiscente
CL2021002277A1 (es) Cruceta en forma de l. (divisional de solicitud 201903255)
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
ECSDI23044051S (es) Molde nuevo sifón de 50mm
TR201902150U5 (tr) Plastik Boru Üretim Hattında Kullanılan Vakum Havuzu
JP1709015S (ja) 置物